Diabetic retinopathy
Conditions
Interventions
Sponsors
Southern Medical University Zhujiang Hospital
Eligibility
Sex/Gender
All
Age
40 Years to 70 Years
Inclusion criteria
Inclusion criteria: the control group included the standard: 1. Age 40-70 years old; 2. No history of diabetes; 3. Patients undergoing eye surgery but without retinal vascular proliferative diseases such as high myopia require vitreous surgery, idiopathic macular hole, idiopathic macular anterior membrane, and rhegmatogenous retinal detachment; 4. Patients with no diabetic retinopathy were diagnosed by slit lamp microscope, binocular indirect ophthalmoscopy, and FFA/OCT examination. the experimental group included standards: 1. Age 40-70 years old; 2. Diagnosis of type 2 diabetes by endocrine diagnosis (according to 2017 American ADA diagnostic criteria: fasting blood glucose =7.0mmol/L, postprandial blood glucose =11.1mmol/L); 3. No history of retinal laser photocoagulation and other intraocular operations; 4. Spleen lamp microscope, binocular indirect ophthalmoscope, FFA/OCT examination confirmed PDR patients, and have surgical indications such as cataract surgery, cataract surgery combined with vitrectomy; 5. Spleen lamp microscope, binocular indirect ophthalmoscope, FFA/OCT examination confirmed PDR patients, and have indications for vitrectomy (non-absorbed vitreous hemorrhage, proliferative DR fibrosis membrane, preretinal hemorrhage, retina) Pull and traction caused retinal detachment, traction hole source mixed retinal detachment; vitreous hemorrhage with cataract, vitreous hemorrhage combined with iris neovascularization, etc.)
Exclusion criteria
Exclusion criteria: 1. Patients with glaucoma or elevated intraocular pressure, with uveitis, ocular trauma, corneal transplantation, fundus vascular diseases such as retinal vein occlusion and macular degeneration, and patients with ocular infections; 2. Patients with systemic diseases such as hypertension, diabetes, hyperthyroidism, coagulopathy, rheumatic immune disease, anemia, malignant tumors; 3. Recently (<4 months) taking anti-VEGF drugs, anticoagulant drugs; oral or topical use of ophthalmic drugs (corticosteroids, vasoactive drugs and non-steroidal anti-inflammatory drugs) during the study period and 1 week before the test Medicine, etc.); 4. Women during pregnancy and lactation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ANRIL;Ang?;AT1R;p65;p52;VEGF; | — |
Countries
China
Contacts
Public ContactMin Fu
Southern Medical University Zhujiang Hospital
Outcome results
None listed